Global Point-of-Care Biopsy Market Report, Industry Analysis and Forecast to 2035

Market Overview

The global Point-of-Care (PoC) Biopsy Market is projected to grow significantly, driven by a compound annual growth rate (CAGR) of 18.9% from 2025 to 2035, reaching a market value of USD 59.18 billion by 2035. This growth is fueled by advancements in diagnostic technologies, increasing demand for rapid and minimally invasive diagnostic tools, and the rising global prevalence of cancer.

Strategic Analysis

Market Size and Share

• 2025 Market Size: Estimated at USD 10.5 billion (projected from current trends in biopsy markets).
• 2035 Market Size: Forecasted to reach USD 59.18 billion.
• Market Share by Type (2025, estimated):
  • Liquid Biopsy: 35% (due to non-invasive nature and advancements in biomarker detection).
  • Tissue Biopsy: 50% (dominant due to established use in oncology).
  • Other Biopsies (e.g., needle, endoscopic): 15%.

Trends

• Technological Advancements: Innovations in point-of-care diagnostics, such as portable biopsy devices and integration of AI for real-time analysis, are transforming the market.
• Non-Invasive Techniques: Growing adoption of liquid biopsies for detecting circulating tumor DNA (ctDNA) and other biomarkers.
• Personalized Medicine: Increased focus on tailoring treatments based on biopsy results, driving demand for precise diagnostic tools.
• AI Integration: Machine learning algorithms enhance diagnostic accuracy and speed, particularly in analyzing biopsy samples.
• Rising Cancer Incidence: Global cancer cases are expected to rise by 77% by 2050, increasing the need for efficient PoC biopsy solutions.

Growth Drivers

• Increasing Cancer Prevalence: The global burden of cancer, with over 20 million new cases in 2022, necessitates rapid diagnostic solutions.
• Demand for Minimally Invasive Procedures: PoC biopsies reduce patient discomfort and recovery time compared to traditional methods.
• Advancements in Genomic Sequencing: Next-generation sequencing (NGS) and PCR-based technologies improve the sensitivity and specificity of PoC biopsies.
• Point-of-Care Accessibility: Portable devices enable diagnostics in remote or underserved areas, expanding market reach.
• Government and Research Funding: Increased investments in cancer diagnostics, such as the USD 6.8 billion allocated to the National Cancer Institute in 2022, support market growth.

Challenges

• Regulatory Hurdles: Stringent FDA approval processes for PoC biopsy devices can delay market entry.
• High Costs: Advanced PoC technologies, such as AI-integrated or NGS-based systems, may limit adoption in low-resource settings.
• Limited Awareness: In developing regions, lack of awareness about PoC biopsy benefits may hinder market growth.

Key Players

Key companies driving the PoC biopsy market include:

• Illumina, Inc.: Leader in NGS technologies for liquid biopsies.
• Guardant Health, Inc.: Known for its Shield multi-cancer detection test and strong presence in liquid biopsy.
• Qiagen N.V.: Offers PCR-based cancer testing solutions for PoC applications.
• Becton, Dickinson, and Company (BD): Provides biopsy instruments and consumables with a focus on minimally invasive solutions.
• F. Hoffmann-La Roche Ltd.: Engages in partnerships for liquid biopsy advancements.
• Exact Sciences Corporation: Develops multi-cancer early detection (MCED) tests.
• Thermo Fisher Scientific, Inc.: Supports genomic profiling for PoC diagnostics.

Market Segmentation

• By Product:
  • Instruments (e.g., portable biopsy devices): 40% share in 2025.
  • Kits & Consumables: 50% share, driven by recurring demand.
  • Services: 10% share.
• By Application:
  • Breast Cancer: 20% share, due to high prevalence.
  • Lung Cancer: 15%.
  • Colorectal Cancer: 12%.
  • Prostate Cancer: 10%.
  • Others (e.g., liver, pancreatic): 43%.
• By Technology:
  • Liquid Biopsy (NGS, PCR): 40% share, fastest-growing segment.
  • Tissue Biopsy (core needle, fine-needle aspiration): 45%.
  • Others (e.g., endoscopic, surgical): 15%.